Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has provided an update.
On March 31, 2025, Shuttle Pharmaceuticals Holdings, Inc. announced a restructuring of its senior management, appointing Christopher Cooper as interim CEO and Dr. Anatoly Dritschilo as Chief Scientific Officer and Chairman of the Board. This restructuring aims to enhance the company’s focus on business and capital markets while allowing Dr. Dritschilo to concentrate on ongoing Phase 2 clinical trials and scientific research, with milestones set for future clinical trial phases.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a Delaware-based company focused on the biotechnology industry, primarily engaged in the development of pharmaceutical products, including clinical trials for treatments such as Ropidoxuridine for glioblastoma.
YTD Price Performance: -54.29%
Average Trading Volume: 134,882
Technical Sentiment Signal: Buy
Current Market Cap: $2.43M
For a thorough assessment of SHPH stock, go to TipRanks’ Stock Analysis page.